Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions... Show more
On August 15, 2025, the Stochastic Oscillator for PGNY moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 64 instances where the indicator left the oversold zone. In of the 64 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Moving Average Convergence Divergence (MACD) for PGNY just turned positive on August 29, 2025. Looking at past instances where PGNY's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
PGNY moved above its 50-day moving average on August 13, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PGNY advanced for three days, in of 334 cases, the price rose further within the following month. The odds of a continued upward trend are .
PGNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 02, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PGNY as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PGNY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.908) is normal, around the industry mean (4.065). PGNY has a moderately high P/E Ratio (39.678) as compared to the industry average of (17.366). PGNY's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (0.861). PGNY's Dividend Yield (0.000) is considerably lower than the industry average of (0.023). PGNY's P/S Ratio (1.705) is slightly higher than the industry average of (0.665).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools
Industry PublishingBooksMagazines